TRAF2 and rectum adenocarcinoma: Our investigation further identified that TRAF2 demonstrated increased expression in a variety of cancer types, including BLCA, breast invasive carcinoma (BRCA), CHOL, COAD, esophageal carcinoma (ESCA), HNSC, KICH, KIRC, KIRP, LIHC, LUAD, LUSC, prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), STAD, and UCEC.